Head to head
Posted: Thu May 11, 2006 7:29 am
The following story is from the Boston Cure Project today.
One has to agree with Art's comment at the end.
Ian
"A two year open-label study comparing Betaseron (called Betaferon in Europe) and Avonex found no substantial differences in relapse rates, time to first relapse, progression of disability, and neutralizing antibody development".
Can we stop spending money on studies of the existing drugs and start looking at some new ones, now?"
One has to agree with Art's comment at the end.
Ian
"A two year open-label study comparing Betaseron (called Betaferon in Europe) and Avonex found no substantial differences in relapse rates, time to first relapse, progression of disability, and neutralizing antibody development".
Can we stop spending money on studies of the existing drugs and start looking at some new ones, now?"